Alnylam Pharmaceuticals, Inc.

( )
ALNY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.48%53.970.9%$1408.01m
JNJJohnson & Johnson -0.05%179.540.7%$1296.44m
BMYBristol-Myers Squibb Co. 0.45%77.591.0%$1212.16m
MRKMerck & Co., Inc. -1.53%92.320.7%$1167.02m
ABBVAbbVie, Inc. -0.92%150.561.9%$1100.30m
LLYEli Lilly & Co. 2.11%313.481.1%$967.28m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.29%142.980.0%$491.89m
AZNAstraZeneca Plc -0.17%66.701.0%$491.50m
NVSNovartis AG 0.01%91.260.2%$259.85m
GSKGlaxoSmithKline Plc -1.23%44.420.2%$257.59m
VERUVeru, Inc. 2.18%12.640.0%$253.71m
HZNPHorizon Therapeutics Plc 2.45%90.595.4%$196.03m
SGENSeagen Inc. 1.46%138.465.7%$185.67m
NVONovo Nordisk A/S 1.30%106.620.1%$182.89m
VTRSViatris, Inc. 1.44%12.010.0%$165.27m

Company Profile

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.